Latest glioblastoma multiforme Stories
PORTSMOUTH, N.H., May 24, 2012 /PRNewswire/ -- Novocure(TM), a commercial stage private oncology company, announced that by June 1, eight additional clinical centers of excellence will join the seven existing clinical centers that provide Novocure's Tumor Treating Fields (TTFields) therapy to patients with recurrent GBM. These fifteen clinical centers are among the leading cancer centers in the U.S. GBM is both the deadliest and most common form of primary brain tumor in the...
PORTSMOUTH, N.H., May 21, 2012 /PRNewswire/ -- Results of the first randomized controlled trial to compare a novel cancer treatment modality delivering Tumor Treating Fields (TTFields) therapy versus chemotherapy in patients with recurrent glioblastoma (GBM) were published in the European Journal of Cancer (Stupp R. et al., NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: A randomized phase III trial of a novel treatment modality, Eur J...
-The system doctors use to classify patients' malignant brain tumors is outdated. -Researchers have revised the system to accommodate treatment advances and molecular markers. -The new system will be validated in future clinical trials for malignant gliomas. Radiation oncology researchers have revised the system used by doctors since the 1990s to determine the prognosis of people with glioblastoma, which is the most devastating of malignant brain tumors. The outdated system was...
PORTSMOUTH, N.H., May 14, 2012 /PRNewswire/ -- In its ongoing effort to help patients, their caregivers and health care professionals easily find detailed information about its NovoTTF(TM) therapy for recurrent glioblastoma, Novocure(TM) today unveiled its U.S.-focused NovoTTF(TM) Therapy Website, found at www.novottftherapy.com. Novocure(TM), a commercial stage private oncology company, manufactures the NovoTTF(TM)-100A,( )a wearable device that delivers tumor treating fields...
Study is first to show feasibility and efficacy of a new use for autologous stem cell transplant For the first time, scientists at Fred Hutchinson Cancer Research Center have transplanted brain cancer patients' own gene-modified blood stem cells in order to protect their bone marrow against the toxic side effects of chemotherapy. Initial results of the ongoing, small clinical trial of three patients with glioblastoma showed that two patients survived longer than predicted if they had not...
Findings from Johns Hopkins scientists hint at why certain brain cancers are so deadly Johns Hopkins researchers have discovered that a protein that transports sodium, potassium and chloride may hold clues to how glioblastoma, the most common and deadliest type of brain cancer, moves and invades nearby healthy brain tissue. The findings, reported in the journal PLoS Biology, also suggest that a cheap FDA-approved drug already on the market could slow movement of glioblastoma cells, and...
ABTA Recognizes May as Brain Tumor Awareness Month Chicago, IL (PRWEB) May 01, 2012 May is Brain Tumor Awareness Month. In acknowledgement of this time of increased attention and awareness, the American Brain Tumor Association (http://www.abta.org) offers these “Top Ten” facts and statistics about brain tumors: 1) More than 600,000 people in the United States are currently living with a brain tumor—approximately 209 out of every 100,000 people....
BETHESDA, Md., May 1, 2012 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTC Bulletin Board: NWBO) (NW Bio) today announced that, working together with the Fraunhofer Institute (IZI), it has received approval of a major grant from the Sachsische Aufbau Bank (SAB or Saxony Development Bank) in Germany. The grant will reimburse fifty percent (50%) of the costs for manufacturing in Germany and for NW Bio's clinical trial with DCVax®-L for brain cancer at up to 30 clinical sites...
NEW YORK, April 18, 2012 /PRNewswire/ -- Stemline Therapeutics, Inc. announced that trial results of two clinical studies of direct injection synthetic peptide vaccine, now being developed as SL-701, in both adults and children with advanced brain cancer were selected for late-breaking presentations at the Annual Meeting of the American Association for Cancer Research (AACR) held from March 31 to April 4, 2012 in Chicago, IL. SL-701 is comprised of synthetic peptides corresponding to...
Connie K. Ho for RedOrbit.com On Tuesday, April 17, researchers from the University of California, San Francisco (UCSF) presented results at the American Association of Neurological Surgeons (AANS) meeting in Miami, Florida that a new brain cancer vaccine tailored to individual subjects had been successful in its second clinical trial. The vaccine is for patients who suffer from recurrent glioblastoma multiforme, a type of cancer, and it has helped extend patients’ lives. The trial...
